Imaging Characteristics and First Experience of [Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [Ga]PSMA I&T.

Purpose: [Ga]Trishydroxypyridinone (THP)-prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [Ga]THP-PSMA.

Procedures: [Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer.

PSA-stratified detection rates for [Ga]THP-PSMA, a novel probe for rapid kit-based Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Purpose: [Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of Ga at low concentration, room temperature and over a wide pH range, using direct elution from a Ge/Ga-generator. We evaluated the clinical detection rates of [Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy.

Methods: Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [Ga]THP-PSMA PET/CT were analyzed retrospectively.